Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol (European Journal of Clinical Pharmacology, (2016), 72, 2, (175-184), 10.1007/s00228-015-1965-1);Genotype and co-medication dependent CYP2D6 metabolic activity: Effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol

European Journal of Clinical Pharmacology

Volumn 72, Issue 2, 2016, Pages 175-184

  Patteet, Lisbeth ^a   Haufroid, Vincent ^b,c   Maudens, Kristof ^a   Sabbe, Bernard ^d,e   Manuel, Manuel ^f   Neels, Hugo ^a,g  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Psychiatric Centre Sint Norbertushuis   (Belgium)

^f Psychiatric Hospital Broeders Alexianen   (Belgium)

^g Stuivenberg General Hospital   (Belgium)

Author keywords

Antipsychotics; CYP2D6; Genotyping; Therapeutic drug monitoring

Indexed keywords

AMFEBUTAMONE; AMIODARONE; ARIPIPRAZOLE; CIMETIDINE; CYTOCHROME P450 2D6; DULOXETINE; FLUOXETINE; HALOPERIDOL; PALIPERIDONE; PAROXETINE; RISPERIDONE; RITONAVIR; SERTRALINE; TERBINAFINE; ZUCLOPENTHIXOL; CLOPENTHIXOL; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIQUID LIQUID EXTRACTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEADY STATE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG MONITORING; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CLOPENTHIXOL; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PALIPERIDONE PALMITATE; YOUNG ADULT;

EID: 84954288543     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2144-8     Document Type: Erratum

References (33)

1. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195-235
2. Haufroid V, Hantson P (2015) CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila):1-10. doi:10.3109/15563650.2015.1049355
3. nomenclature CDa (Last accessed on June 2015) CYP2D6 Allele nomenclature. http://www.cypalleles.ki.se/cyp2d6.htm.
4. Steimer W (2010) Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit 32(4):381-386. doi: 10.1097/FTD.0b013e3181e1a78d
5. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25(4):193-200. doi: 10.1016/j.tips.2004.02.007
6. Antunes MV, de Oliveira V, Raymundo S, Staudt DE, Gossling G, Biazus JV, Cavalheiro JA, Rosa DD, Mathy G, Wallemacq P, Linden R, Schwartsmann G, Haufroid V (2015) CYP3A4 22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. Pharmacogenomics 16(6):601-617. doi: 10.2217/pgs.15.13
7. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442-473. doi: 10.1038/sj.mp.4001494
8. Luo HR, Gaedigk A, Aloumanis V, Wan YJ (2005) Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 61(11):797-802. doi: 10.1007/s00228-005-0044-4
9. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72(4):438-452. doi: 10.1067/mcp.2002.127494
10. van Schaick RHN, Grandia L, de Goede A, Bet PM, Bekers O, Guchelaar HJ, Goldschmidt HMJ, Meijer MMC, Mulder H, van Der Weide J, Deneer VHM (2008) Nederlandse consensus: CYP2D6 genotype '1-0' ingedeeld als intermediaire metaboliseerder. Ned Tijdschr Klin Chem Labgeneesk 33:52-53
11. Shin JG, Kane K, Flockhart DA (2001) Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 51(1):45-52
12. Kudo S, Ishizaki T (1999) Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 37(6):435-456. doi: 10.2165/00003088-199937060-00001
13. Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H (2014) High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 429:51-58. doi: 10.1016/j.cca.2013.11.024
14. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234-242. doi: 10.1038/sj.clpt.6100406
15. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50(4):450-458. doi: 10.1177/0091270009359182
16. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91(2):321-326. doi: 10.1038/clpt.2011.287
17. Hendset M, Hermann M, Lunde H, Refsum H, Molden E (2007) Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 63(12):1147-1151. doi: 10.1007/s00228-007-0373-6
18. Spina E, de Leon J (2015) Clinical applications of CYP genotyping in psychiatry. J Neural Transm 122(1):5-28. doi: 10.1007/s00702-014-1300-5
19. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ (2011) Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 89(5):662-673. doi: 10.1038/clpt.2011.34
20. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA (2013) Applications of CYP450 testing in the clinical setting. Molecular Diagnosis & therapy 17(3):165-184. doi: 10.1007/s40291-013-0028-5
21. Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 31(6):655-660
22. Pan L, Belpaire FM (1999) In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 55(8):599-604
23. van der Weide K, van der Weide J (2015) The influence of the CYP3A4 22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol 35(3):228-236. doi: 10.1097/JCP.0000000000000319
24. Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34(6):629-651. doi: 10.1097/FTD.0b013e3182708ec5
25. Aravagiri M, Marder SR, Van Putten T, Marshall BD (1994) Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. J Chromatogr B Biomed Appl 656(2):373-381
26. Pan L, Rosseel MT, Belpaire FM (1998) Comparison of two high-performance liquid chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 20(2):224-230
27. Murray M (2006) Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58(7):871-885. doi: 10.1211/jpp.58.7.0001
28. Hendset M, Molden E, Refsum H, Hermann M (2009) Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 29(6):537-541. doi: 10.1097/JCP.0b013e3181c17df0
29. Gunes A, Spina E, Dahl ML, Scordo MG (2008) ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 30(5):628-633. doi: 10.1097/FTD.0b013e3181858ca9
30. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. The Journal of Clinical psychiatry 66(1):15-27
31. Linnet K, Wiborg O (1996) Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 18(6):629-634
32. Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, Sjoqvist F (1996) The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 59(4):423-428. doi: 10.1016/S0009-9236(96)90111-3
33. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vaan S, Svensson JO, Dahl ML (2002) Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 162(1):67-73. doi: 10.1007/s00213-002-1059-5